Rua Bioscience Limited — Director's Dealing 2020

Nov 13, 2020

==> picture [104 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Rua Bioscience Limited Date this disclosure made: 13-Nov-20 Date of last disclosure: 22-Oct-20 Director or senior manager giving disclosure Full name(s): Panapa Ehau Name of listed issuer: Rua Bioscience Limited Name of related body corporate (if applicable): Position held in listed issuer: Director of Rua Bioscience Limited Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Ordinary shares in Rua Bioscience Class of affected quoted financial products: Limited Nature of the affected relevant interest(s): Registered and beneficial holder For that relevant interest- Number held in class before acquisition or disposal: 252,293 Number held in class after acquisition or disposal: 279,392 Current registered holder(s): New share issue Registered holder(s) once transfers are registered: Panapa Ehau Summary of acquisition or disposal of specified derivatives relevant interest (if applicable) Type of affected derivative: N/A Class of underlying financial products: N/A Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): N/A A statement as to whether the derivative is cash settled or physically settled: N/A Maturity date of the derivative (if any): N/A Expiry date of the derivative(if any): N/A The price specified in the terms of the derivative (if any): N/A Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: N/A For that derivative,- N/A Parties to the derivative: N/A If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: N/A Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):

13-Nov-20 Acquisition of legal and beneficial interest in 27,099 ordinary shares in accordance with Rua Bioscience Limited's employee share bonus offer Services provided to Rua Bioscience Limited 27,099

No N/A N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Ordinary shares in Rua Bioscience Limited Director and shareholder of Waiapu Investments Limited ( WIL ). WIL is the registered holder and beneficial owner of 726 shares in Rua Bioscience Limited 726 Waiapu Investments Limited N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):

Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan

55,000 options potentially convertible to 283,072 ordinary shares N/A N/A N/A N/A N/A

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,- Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or Signature of person authorised to sign on behalf of director or officer: Date of signature:

Name and title of authorised person:

==> picture [93 x 36] intentionally omitted <==

13-Nov-20

==> picture [137 x 48] intentionally omitted <==

==> picture [104 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Date this disclosure made: Date of last disclosure: Director or senior manager giving disclosure Full name(s): Name of listed issuer: Name of related body corporate (if applicable): Position held in listed issuer: Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Rua Bioscience Limited 13-Nov-20 22-Oct-20 Rob Mitchell Rua Bioscience Limited Chief Executive Officer of Rua Bioscience Limited

Ordinary shares in Rua Bioscience Class of affected quoted financial products: Limited Nature of the affected relevant interest(s): Registered and beneficial holder For that relevant interest- Number held in class before acquisition or disposal: 40,000 Number held in class after acquisition or disposal: 110,320 Current registered holder(s): New share issue Registered holder(s) once transfers are registered: Rob Mitchell Summary of acquisition or disposal of specified derivatives relevant interest (if applicable) Type of affected derivative: N/A Class of underlying financial products: N/A Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): N/A A statement as to whether the derivative is cash settled or physically settled: N/A Maturity date of the derivative (if any): N/A Expiry date of the derivative(if any): N/A The price specified in the terms of the derivative (if any): N/A Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: N/A For that derivative,- N/A Parties to the derivative: N/A If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: N/A Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction: Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):

13-Nov-20 Acquisition of legal and beneficial interest in 70,320 ordinary shares in accordance with Rua Bioscience Limited's employee share bonus offer Services provided to Rua Bioscience Limited 70,320

No N/A N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan

55,000 options potentially convertible to 301,453 ordinary shares N/A

N/A

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

==> picture [89 x 65] intentionally omitted <==

13-Nov-20

==> picture [137 x 47] intentionally omitted <==

==> picture [104 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Date this disclosure made: Date of last disclosure: Director or senior manager giving disclosure Full name(s): Name of listed issuer: Name of related body corporate (if applicable): Position held in listed issuer: Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Rua Bioscience Limited 13-Nov-20 22-Oct-20 Hamish White Rua Bioscience Limited Chief Financial Officer of Rua Bioscience Limited

Ordinary shares in Rua Bioscience Class of affected quoted financial products: Limited Nature of the affected relevant interest(s): Registered and beneficial holder For that relevant interest- Number held in class before acquisition or disposal: 99,990 Number held in class after acquisition or disposal: 126,048 Current registered holder(s): New share issue Registered holder(s) once transfers are registered: Hamish White Summary of acquisition or disposal of specified derivatives relevant interest (if applicable) Type of affected derivative: N/A Class of underlying financial products: N/A Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): N/A A statement as to whether the derivative is cash settled or physically settled: N/A Maturity date of the derivative (if any): N/A Expiry date of the derivative(if any): N/A The price specified in the terms of the derivative (if any): N/A Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: N/A For that derivative,- N/A Parties to the derivative: N/A If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: N/A Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction: Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):

13-Nov-20 Acquisition of legal and beneficial interest in 26,058 ordinary shares in accordance with Rua Bioscience Limited's employee share bonus offer Services provided to Rua Bioscience Limited 26,058

No N/A N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan

55,000 options potentially convertible to 283,072 ordinary shares N/A

N/A

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

==> picture [99 x 45] intentionally omitted <==

13-Nov-20

==> picture [137 x 47] intentionally omitted <==

==> picture [104 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Rua Bioscience Limited Date this disclosure made: 13-Nov-20 Date of last disclosure: 22-Oct-20 Director or senior manager giving disclosure Full name(s): Paul Naske Name of listed issuer: Rua Bioscience Limited Name of related body corporate (if applicable): Chief Operating Officer of Rua Position held in listed issuer: Bioscience Limited Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Ordinary shares in Rua Bioscience Class of affected quoted financial products: Limited Nature of the affected relevant interest(s): Registered and beneficial holder For that relevant interest- Number held in class before acquisition or disposal: 20,880 Number held in class after acquisition or disposal: 46,938 Current registered holder(s): New share issue Registered holder(s) once transfers are registered: Paul Naske Summary of acquisition or disposal of specified derivatives relevant interest (if applicable) Type of affected derivative: N/A Class of underlying financial products: N/A Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): N/A A statement as to whether the derivative is cash settled or physically settled: N/A Maturity date of the derivative (if any): N/A Expiry date of the derivative(if any): N/A The price specified in the terms of the derivative (if any): N/A Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: N/A For that derivative,- N/A Parties to the derivative: N/A If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: N/A Details of transactions giving rise to acquisition or disposal Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-

Date of transaction:

Nature of transaction:

Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):

13-Nov-20 Acquisition of legal and beneficial interest in 26,058 ordinary shares in accordance with Rua Bioscience Limited's employee share bonus offer Services provided to Rua Bioscience Limited 26,058

No N/A N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan

32,000 options potentially convertible to 164,696 ordinary shares N/A N/A

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

==> picture [96 x 38] intentionally omitted <==

13-Nov-20

==> picture [137 x 47] intentionally omitted <==